TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis.
The aim of this study was to assess the value of TPS and CA 19-9 in a long-term follow-up analysis of 11 patients with chronic pancreatitis (CP) and 15 patients with pancreatic cancer (PC). In all monitored patients with chronic pancreatitis the initial TPS level was below 200 U/L, whereas CA 19-9 was elevated in two of them. In one patient a dramatic increase in the TPS concentration (820 U/L) was measured at the last follow-up visit (after 8.6 months), which led to the detection of PC. In all patients with PC the preoperative TPS level exceeded 200 U/L, whereas CA 19-9 was elevated in only nine patients. After the Kausch-Whipple operation 11 patients showed no evidence of disease and in eight of these patients both TPS and CA 19-9 were within the reference range; however, in three patients liver metastases were detected after 8-24 months from the last tumor marker measurement. In four of the 15 patients both markers were elevated at the end of the follow-up period and distant metastases were clinically confirmed. Our results indicate that in patients with CP and PC undergoing long-term follow-up, TPS reflects the clinical status of patients more accurately than CA 19-9.
Slesak
B
B
Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland. slesak@immuno.am.wroc.pl
Harlozinska-Szmyrka
A
A
Knast
W
W
Sedlaczek
P
P
Einarsson
R
R
van Dalen
A
A
D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000401:mortality; D010195:Pancreatitis / Q000097:blood* / Q000150:complications; D010455:Peptides / Q000097:blood*; D012372:ROC Curve; D013997:Time Factors
D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D010455:Peptides; C089984:tissue polypeptide specific antigen